Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report) by 82.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,159 shares of the company’s stock after selling 165,333 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.08% of Voyager Therapeutics worth $265,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Voyager Therapeutics during the second quarter worth $30,000. Gladius Capital Management LP purchased a new stake in Voyager Therapeutics during the 3rd quarter worth about $25,000. UBS Group AG purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $39,000. BNP Paribas Arbitrage SNC grew its holdings in Voyager Therapeutics by 12,170.6% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 8,344 shares of the company’s stock valued at $96,000 after buying an additional 8,276 shares during the period. Finally, PDT Partners LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth about $60,000. 58.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on VYGR shares. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.00.

View Our Latest Stock Analysis on VYGR

Voyager Therapeutics Stock Up 0.7 %

Shares of NASDAQ VYGR opened at $7.48 on Friday. Voyager Therapeutics, Inc. has a 12 month low of $6.06 and a 12 month high of $14.34. The company has a market cap of $329.05 million, a price-to-earnings ratio of 6.08 and a beta of 0.98. The business has a fifty day simple moving average of $8.01 and a 200-day simple moving average of $8.00.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last issued its earnings results on Monday, November 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.01). The business had revenue of $4.61 million during the quarter, compared to the consensus estimate of $1.75 million. As a group, sell-side analysts expect that Voyager Therapeutics, Inc. will post 1.1 EPS for the current fiscal year.

Voyager Therapeutics Profile

(Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.

Further Reading

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.